Physician profile
Mario Marotta
NPI 1871591453
$988.19
in general payments reported to CMS, 2019-2025
10 companies · $404 in 2025
The $404 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $129 · 2022: $170 · 2023: $62.84 · 2024: $98.31 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.19 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $197.83 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Travere Therapeutics, INC. | $190.50 | 2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $150.62 | 2021-2024 | Farxiga |
| Nestle Healthcare Nutrition INC. | $125.00 | 2022 | |
| Ironwood Pharmaceuticals, INC | $125.00 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $112.80 | 2022-2024 | Jynarque |
| Globus Medical, INC. | $30.98 | 2025 | Senza |
| Akebia Therapeutics INC | $21.90 | 2025 | Vafseo |
| Fresenius USA Marketing, INC. | $19.96 | 2024 | Velphoro |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Marotta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.